Drugs / PLX7486
PLX7486
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01804530 | Aug 2013 → Jan 2018 | NTRK fusion positive cancer, tenosynovial giant cell tumor | Plexxikon | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PLX7486 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01804530 ↗ |
| Action | Inhibit | “Macrophage colony stimulating factor receptor inhibitor” CHEMBL3545381 ↗3“Neurotrophic tyrosine kinase receptor type 2 inhibitor” CHEMBL3545381 ↗ “Nerve growth factor receptor Trk-A inhibitor” CHEMBL3545381 ↗ “NT-3 growth factor receptor inhibitor” CHEMBL3545381 ↗ |
| Target | CSF1R | “Macrophage colony stimulating factor receptor inhibitor” CHEMBL3545381 ↗ |
| Target | NTRK1 | “Nerve growth factor receptor Trk-A inhibitor” CHEMBL3545381 ↗ |
| Target | NTRK2 | “Neurotrophic tyrosine kinase receptor type 2 inhibitor” CHEMBL3545381 ↗ |
| Target | NTRK3 | “NT-3 growth factor receptor inhibitor” CHEMBL3545381 ↗ |